Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

April 28, 2008

More potential developments in chronic lymphatic leukemia (CLL) therapy!

Analysis of: IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro | bloodjournal.hematologylibrary.org
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Analysis By:
Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CCKenneth Algazy, MD 
Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC
Implications: ZymoGenetic appears to have a biologic that will expedite lymphocytes apoptosis (destruction) when combined with Fludara and Rituxan- 2 standard agents in this rather common & occasional refractory condition.

Analysis: Cephalon just received approval for Treanda in CLL and now  ZymoGenetic
has IL-21!! Rather impressive logarithmic jumps in our ability to treat this sometimes refractory disease. http://bloodjournal.hematologylibrary.org/cgi/content/full/111/9/4424-a
outlines other possible uses so this is not just a "one trick pony." Stay tuned


Report a Concern

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics